Development of a high-yield and high-purity isolation kit for extracting extracellular vesicles from complex biological samples

拟议的研究项目包括圭尔夫大学（UofG，圭尔夫，安大略省）的生物医学创新（BMI）实验室（李博士）和Galenvs Sciences Inc.（蒙特利尔，魁北克）之间的合作伙伴关系。合作研究伙伴关系的主要目标是开发一种EV分离试剂盒，以高产量和高纯度从复杂的生物流体（如血浆/血清、尿液）中分离和纯化细胞外囊泡（EV）。电动汽车是纳米级的囊泡，从细胞分泌到血液和尿液等体液中。由于电动汽车携带与其来源细胞相似的生物分子，因此分析生物体液中的电动汽车含量已成为疾病诊断和治疗监测的有前途的工具。ev（特别是外泌体）也有能力作为治疗复杂疾病的治疗平台，具有低免疫原性和致瘤性。然而，由于当前技术的产量和纯度限制，从生物流体中分离EV是这些应用的主要瓶颈。该项目旨在通过开发一种适配体功能化磁性纳米颗粒提取试剂盒来克服这些挑战，该试剂盒具有易于遵循的协议和现成的试剂，用于从各种类型的生物流体中分离EV，具有高产量和纯度，适用于下游EV分子分析。该项目的成功完成对加拿大生物技术产业具有重大的经济影响。潜在的结果和影响包括：(1)加拿大制造的首批EV分离试剂盒之一，既有既定的方案，也有现成的试剂；(2)促进电动汽车在健康和生命科学领域的更广泛应用；(3)提高加拿大生物技术公司在国内和国际市场上的竞争力；(4)纳米生物技术和电动汽车科学HQP培训。

The proposed research project includes a partnership between the BioMed Innovation (BMI) laboratory (Dr. Li) at the University of Guelph (UofG, Guelph, Ontario) and Galenvs Sciences Inc. (Montreal, Quebec). The primary goal of the collaborative research partnership is to develop an EV isolation kit to isolate and purify extracellular vesicles (EVs) from complex biological fluids (e.g., blood plasma/serum, urine) with high yield and high purity. EVs are nanoscale vesicles secreted from cells into body fluids such as blood and urine. Since EVs carry biomolecules similar to their cells of origin, analysis of EV contents in biofluids has been a promising tool for disease diagnosis and treatment monitoring. EVs (specifically, exosomes) also have the capacity to serve as a therapeutic platform to treat complex diseases, with low immunogenicity and tumorigenicity. However, EV isolation from biofluids constitutes a major bottleneck in these applications largely due to the yield and purity limitations of the current technologies. This project aims to overcome these challenges by developing an aptamer-functionalized-magnetic-nanoparticle-based extraction kit with easy-to-follow protocols and ready-to-use reagents for isolating EVs from various types of biofluids, with high yield and purity, suitable for downstream EV molecular analysis. Successful completion of this project has a substantial economic impact on the biotech industry of Canada. The potential outcomes and impacts include: (1) one of the first EV isolation kits made in Canada with both established protocols and ready-to-use reagents; (2) enabling broader applications of EVs in health and life sciences; (3) enhancing the competitiveness of the Canadian biotechnology companies both at home and in the global market; (4) training of HQP in nano-biotechnology and EV science.